Lumen to earn up to $14.5 million from CARB-X for antidiarrheal

by admin | Feb 12, 2021 | Press Release

Expression and manufacturing of protein therapeutics in spirulina

by admin | Jan 27, 2021 | Publications

Read on bioRxiv Expression and manufacturing of protein therapeutics in spirulina View ORCID ProfileBenjamin Jester, Hui Zhao, Mesfin Gewe, Thomas Adame, Lisa Perruzza, David Bolick, Jan Agosti, Nhi Khuong, Rolf Kuestner, Caitlin Gamble, Kendra Cruickshank, Jeremy...

Lumen Bioscience Receives CARB-X Award to Develop Preventative for Deadly Diarrheal Diseases and Details Broad Potential of Spirulina Platform

by admin | Jan 27, 2021 | Press Release

Seattle, WA, January 27, 2021 – Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drug candidates for highly prevalent diseases, today announced initiation of an up to $14.5 million project funded by CARB-X to develop an oral monoclonal...

Lumen bags U.S. grant for GI-focused COVID-19 antibody cocktail

by admin | Nov 23, 2020 | Press Release

Lumen Bioscience reels in $16M Series B to democratize biologics

by admin | Nov 23, 2020 | Press Release